Merz Therapeutics GmbH

Merz Therapeutics GmbH is a global healthcare company dedicated to developing and distributing innovative therapeutic solutions, primarily focusing on neurology. The company's core mission is to deliver better outcomes for more patients by pursuing innovation that benefits both individuals and society. Headquartered in Frankfurt am Main, Germany, Merz Therapeutics operates as a distinct business division within the privately held Merz Group.

The company's portfolio encompasses therapies in neurology, hepatology, and dermatology, with a strong emphasis on addressing movement disorders and neurodegenerative conditions. Key products include Xeomin® (incobotulinumtoxinA) for various movement disorders, Ampyra® (alfampridine) for multiple sclerosis, and Inbrija® (levodopa) for Parkinson's disease. Merz Therapeutics also offers products like Coaptite®, Cuvposa® (glycopyrrolate), and Prolaryn® Gel and Prolaryn® Plus, leveraging its expertise in botulinum neurotoxin technology.

Established as a standalone entity in 2020, Merz Therapeutics aims to be a leading player in neurology-focused specialty pharmaceuticals. Stefan König has served as the managing director since 2023. In a notable development in 2024, the company acquired Inbrija and Ampyra from Acorda Therapeutics for $185 million, significantly expanding its treatment options for Parkinson's disease and multiple sclerosis. Furthermore, in June 2026, Merz Therapeutics strengthened its partnership with Grünenthal to commercialize XEOMIN® in Brazil, reinforcing its global market position across more than 80 countries.